Singapore-based venture capital firm Vertex Holdings has announced the appointment of Dilhan Pillay Sandrasegara, Executive Director and Chief Executive Officer of Temasek Holdings, as Chairman of the Board with effect from April 15.

This marks the next phase in the company’s transformation as Temasek prepares to derive greater synergy with its other funding platforms， Vertex said in a statement on last Friday.

As part of this transition, Chairman Teo Ming Kian and Deputy Chairman Lee Kheng Nam will retire from the board.

The board will continue to review its composition to ensure strong governance and diverse international perspectives.

Meanwhile, for the financial year ended FY2025, Vertex reported a profit of over $100 million, reflecting strong portfolio performance, capital discipline and consistent value realization across market cycles.

This performance reflects the strength of a global portfolio built over multiple investment cycles and supported by outcomes achieved across both private and public markets.

For 2024/2025, the Vertex Group has delivered a series of meaningful private market exits, including the acquisition of EyeBio by Merck for up to $3 billion, Salesforce’s acquisition of Own Company for $2.1 billion, the sale of Adaptive Shield to CrowdStrike for $300 million, and a secondary sale in Guesty for $800 million.

In public markets, Geek+ was listed in 2025 at a market capitalization of approximately $2.8 billion, subsequently reaching a peak of around $5 billion.

Horizon Robotics, which listed in 2024 at a market capitalization of approximately $6.7 billion, has since seen its market capitalization grow to approximately $13 billion (as of early April 2026), demonstrating sustained investor confidence in the business.

Vertex continues to hold shares in both companies.

Entering 2026, the group has continued to see positive momentum.

In January 2026, Edge Medical, a portfolio company of Vertex China Fund IV, was successfully listed on the Hong Kong Stock Exchange at a valuation of approximately $2 billion.

In addition, Cymbio, a portfolio company of Vertex Israel Fund V, was acquired by PayPal at a valuation of approximately $160 million, and XConn, a portfolio company of Vertex China Fund V, was acquired by Marvell Technology at a valuation of approximately $540 million, underscoring ongoing strategic demand for high-quality companies within the Vertex portfolio.

SpyGlass Pharma, a portfolio company of Vertex Ventures HC focused on innovative sustained-drug delivery solutions for chronic eye conditions, also completed its IPO on the Nasdaq in early February 2026, further reflecting continued momentum across the group’s healthcare investments.

Subject to market conditions, the group has at least five portfolio companies at advanced stages of market readiness and expects these companies to pursue public listings over the next 12 months across major global exchanges, including the Hong Kong Stock Exchange, Nasdaq, the New York Stock Exchange, and leading Indian and mainland China stock exchanges.

It is therefore expected that distributions from underlying funds will grow in the next two years.

It is noted that Vertex operates a global venture capital platform spanning Southeast Asia, India, China, Israel, United States, Korea and Japan.

The group and its network of funds manage close to $7 billion in assets under management, with a significant portion raised from global institutional investors.

The group provides a unique platform that enables portfolio value-creation, growth and realization leveraging the domain knowledge and local networks of its global partners.

According to the statement, Sandrasegara has had a longstanding association with Vertex, including during his tenure as Senior Managing Director of Temasek and Head of the Enterprise Development Group, where Vertex was under his purview.

He also served on the Vertex board from 2015 to 2018.

Working closely with Chairman Teo and Chief Executive Officer Chua Kee Lock, Vertex transformed into its current global network structure, with its funds increasingly supported by a diversified base of global institutional investors.

Vertex served as the anchor limited partner (LP), with investment professionals committing capital alongside it as part of an alignment-of-interest structure within a standard LP-GP arrangement.

Sandrasegara was also instrumental in the establishment of Vertex Growth, which further strengthened the platform’s ability to support promising companies within the Vertex Network.

Building on this, Vertex Growth went on to secure significant capital commitments from leading global investors.

“We are on a continuing journey of transformation across the Vertex Group. Our relentless focus on human potential, capacity development and entrepreneurship will continue unabated,

“We have a strong leadership team, with diverse strengths and experiences. Leveraging our global network partnerships, I am confident that we are in a good position to embrace opportunities that will drive innovation and growth in Singapore, and beyond,” said Sandrasegara.

Temasek appoints Piyush Gupta as India Chairman